Accell Non-targeting Control Pool

siRNA delivery without a transfection reagent


A negative control pool of four siRNAs to determine baseline cellular response to Accell siRNA application. Component siRNAs are designed to target no human, mouse, or rat genes.
The Accell Non-Targeting Control Pool is designed to aid in the interpretation of experiments with Accell siRNA reagents as highly reliable controls for assessment of baseline cellular responses. Each of the four component siRNAs is designed with no homology to known human, mouse, or rat genes. RNAi experiments should include a non-targeting siRNA or pool as a control for non-sequence-specific effects. Changes in mRNA or protein levels in cells treated with these controls reflect a non-specific baseline cellular response that can be compared to the levels in cells treated with target-specific siRNA.

Highlights

  • Pool of four siRNAs designed to have minimal targeting of known genes in human, mouse, and rat cells
  • Modified with patent-pending Accell modification pattern to enable uptake by difficult-to-transfect cells
  • Accell modifications also provide stability against nuclease-mediated degradation

Experimental considerations

  • Accell siRNA works at a higher concentration than conventional siRNA; recommended 1 µM working concentration
  • Delivery may be inhibited by the presence of BSA in serum. Optimization studies with serum-free media formulations (Accell Delivery Media) or < 2.5% serum in standard media is recommended
  • Full-serum media can be added back after 48 hours of incubation. Optimal mRNA silencing is typically achieved by 72 hours, or up to 96 hours for protein knockdown
  
CategoryName
HazardousNo
Hazardous:No
Shelf Life:
Shipping ConditionAmbient
Shipping Condition:
Shipping Information
SpecificationName
SpecificationValue
Stability at Recommended Storage ConditionsAt least 12 months
Storage Condition-20 C
Storage Condition:
Cell types demonstrating effective silencing with Accell siRNA

Cell types demonstrating effective silencing with Accell siRNA

Cell types demonstrating effective silencing with Accell siRNA

Internal validation and peer-reviewed publications report numerous successes with difficult-to-transfect cell types. See the References tab for a list of publications.


The Accell siRNA application protocol simplifies targeted gene knockdown

The Accell siRNA application protocol simplifies targeted gene knockdown

The Accell siRNA application protocol simplifies targeted gene knockdown

(A) Combine Accell siRNA with Accell delivery media (or other low- or no-serum media). (B) Add Accell delivery mix directly to cells and incubate for 72 hours.


References

  1. View the published references citing successful Accell siRNA application.

Citations

  1. Accell siRNA reagents in neuronal cells

    S. Suzuki et al., Differential Roles of Epac in Regulating Cell Death in Neuronal and Myocardial Cells. J. Biol. Chem. 285, 24248-24259 (Jul 2010). [primary mouse cortical neurons (E15-17)]

    A. M. Dolga et al., TNF-alpha-mediates neuroprotection against glutamate-induced excitotoxicity via NF-kappaB-dependent up-regulation of K2.2 channels. J. Neurochem. 107(4), 1158-1167 (November 2008). [mouse primary cortical neurons]

    U. Dreses-Werringloer et al., A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, Ab Levels, and Alzheimer’s Disease Risk. Cell. 133(7), 1149-1161 (27 June 2008). [SHSY-5Y; human neuroblastoma]

    J. Sebo et al., Requirement for Protein Synthesis at Developing Synapses. J. Neurosci. 29(31), 9778-9793 (5 August 2009). [rat primary hippocampal neurons]

    P. Mergenthaler et al., Mitochondrial hexokinase II (HKII) and phosphoprotein enriched in astrocytes (PEA15) form a molecular switch governing cellular fate depending on the metabolic state. PNAS USA. 109(5), 1518-1523 (31 January 2012).  [extended duration silencing in rat primary cortical neurons]

  2. Accell siRNA reagents in immunological cells

    S. Winning et al., Acute Hypoxia Induces HIF-Independent Monocyte Adhesion to Endothelial Cells through Increased Intercellular Adhesion Molecule-1 Expression: The Role of Hypoxic Inhibition of Prolyl Hydroxylase Activity for the Induction of NF-B J. Immunology. 185, 1786 -1793 (July 2010). [THP-1 monocytes]

    V. Saini et al.,CXC Chemokine Receptor 4 Is a Cell Surface Receptor for Extracellular Ubiquitin. J. Biol. Chem. 285(20), 15566-15576 (14 May 2010). [THP-1 monocytes]

    J. W. Perry et al., Endocytosis of Murine Norovirus 1 into Murine Macrophages Is Dependent on Dynamin II and Cholesterol. J. Virol. 84(12), 6163-6176 (June 2010). [murine macrophages]

    M. Steenport et al., Matrix Metalloproteinase (MMP)-1 and MMP-3 Induce Macrophage MMP-9: Evidence for the Role of TNF-a and Coclooxygenase-2. J. Immunology. 183(12), 8119-8127 (15 December 2009) [RAW264.7 macrophages, doi:10.4049/jimmunol.0901925]

    C. B. Lai et al.Creation of the two isoforms of rodent NKG2D was driven by a B1 retrotransposon insertion. Nucleic Acids Res. (2009). [mouse NK cell line, gkp174]

    N. Mookherjee et al., Intracellular Receptor for Human Host Sefense Peptide LL-37 in Monocytes. J. Immunol. 183(4), 2688-2696 (15 August 2009). [THP-1; human monocytes]

    D. Smirnov et al., Genetic Analysis of Radiation-induced Changes in Human Gene Expression. Nature. 459(7246), 587-591 (28 May 2009). [immortalized B cells]

    A. M. McElligott et al., The Novel Tubulin-Targeting Agent Pyrrolo-1,5-Benzoxazepine-15 Induces Apoptosis in Poor Prognostic Subgroups of Chronic Lymphocytic Leukemia. Cancer Research. 69(21), 8366-8375 (13 October 2009). [PGA-1; EBV-transformed chronic lymphocyctic leukemia (CLL) B cell line, 10.1158/0008-5472.CAN-09-0131]

  3. Accell siRNA reagents in vivo

    H. Nakajima et al., A rapid, targeted, neuron-selective, in vivo knockdown following a single intracerebroventricular injection of a novel chemically modified siRNA in the adult rat brain. J. Biotechnology. 157(2), 326-333 (20 January 2012). [brain injection]

    E. Gonzalez-Gonzalez et al., Silencing of Reporter Gene Expression in Skin Using siRNAs and Expression of Plasmid DNA Delivered by a Soluble Protrusion Array Device (PAD). Molecular Therapy.  18(9), 1667-1674 (September 2010). [mouse intradermal injection, doi:10.1038/mt.2010.126]

    P. Bonifazi et al., Intranasally Delivered siRNA Targeting PI3K /Akt /mTOR Inflammatory Pathways Protects from Aspergillosis. Mucosal Immuno. 3(2), 193-205 (18 November 2009) [doi:10.1038/mi.2009.130, in vivo intranasal delivery]

    A. DiFeo et al., KLF6-SV1 Is a Novel Antiapoptotic Protein That Targets the BH3-Only Protein NOXA for Degradation and Whose Inhibition Extends Survival in an Ovarian Cancer. Model Cancer Res. 69(11), 4733–4741 (12 May 2009). [in vivo mouse model]

    Q. Li et al., Silencing MAP Kinase-activated Protein Kinase -2 Arrests Inflammatory Bone Loss. J. Pharmacol. Exp. Ther. 336(3), 633-642 (March 2011). [direct injection to rat gingival tissue; in vivo model of periodontal bone loss]

  4. Accell siRNA reagents in primary, stem, tumor and other cell types

    M. Liao et al., Inhibition of Hepatic Organic Anion-transporting Polypeptide by RNA Interference in Sandwich-cultured Human Hepatocytes: An in vitro Model to Assess Transporter-mediated Drug-drug Interactions.Drug Metabolism and Deposition. 38(9), 1612-1622 (August 2010). [freshly isolated human hepatocytes]

    S. Byas et al., Human Embryonic Stem Cells Maintain Pluripotency after E-Cadherin Expression Knockdown.FASEB J. 24, lb172 (April 2010). [H9 stem cell lines]

    S. Desai et al., PRDM1 Is Required for Mantle Cell Lymphoma Response to Bortezomib Mol.Cancer Res. 8, 907-918 (June 2010).

    I. Barbieri et al., Constitutively Active Stat3 Enhances Neu-Mediated Migration and Metastasis in Mammary Tumors via Upregulation of Cten. Cancer Res. 70, 2558-2567 (March 2010).

    C. Bartholomeusz et al., PEA-15 Induces Autophagy in Human Ovarian Cancer Cells and is Associated with Prolonged Overall Survival. Cancer Res. 68, 9302-9310 (2008). [OVCA 420; ovarian carcinoma]

    B. Tunquist et al., Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520.Mol. Cancer Ther. 9, 2046–2056 (July 2010). [multiple myeloma cell lines]

    M. Chetane et al., Interleukin-7 mediates glucose utilization in lymphocytes through transcriptional regulation of the hexokinase II gene.Am. J. Physiol. Cell. Physiol. 298(6), C1560-C1571 (Jun 2010). [lymphocytes]

    G. A. Peters et al., The double-stranded RNA-binding protein, PACT, is required for postnatal anterior pituitary proliferation. PNAS. 106(26), 10696-10701 (30 June 2009). [GH3; rat somatolactotrophs (pituitary cell line) and LßT2 gonadotrophs; basophilic cell of the anterior pituitary]